Related Experiment Video
Updated: May 30, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
[Effects of HO-1 gene expression on proliferation of imatinib resistant CML cells]
Ji-Shi Wang1, Bai-Sheng Chai, Qin Fang
1Department of Hematology, Affiliated Hospital of Gui Yang Medical College, Guiyang 550004, China.
Objective:
To investigate the effect of heme oxygenase-1 (HO-1) expression on cell growth and apoptosis in imatinib resistant chronic myeloid leukemia (CML) cells (K562/A02-IM), and explore the relationship between HO-1 gene and CML.
Methods:
The expression of HO-1 in 20 drug-resistant CML patients was detected by RT-PCR. Different concentrations of hemin were used to induce HO-1 expression of K562/A02-IM, HO-1 expression at different time was detected by RT-PCR and Western blot analysis. Cell apoptosis was detected by Annexin V/PI staining, and MTT assay was used to detect viability of K562/A02-IM cells after induction or inhibition of HO-1 gene by hemin and zinc protoporphyrin (ZPP).
Results:
RT-PCR showed that HO-1 was expressed in the bone marrow mononuclear cells (BMMNCs). When treated with hemin at different concentrations (0, 10, 20, 40 µmol/L) for 16 h, the expression of HO-1 in K562/A02-IM was increased in a dose-dependent manner, and peaked at 20 µmol/L of hemin for 16 h. The apoptosis rates were (17.61 ± 0.01)%, (12.13 ± 0.11)%, (7.94 ± 0.03)% and (4.62 ± 0.15)% at 0,10, 20 and 40 µmol/L of hemin respectively for 16 h and were (14.7 ± 0.05)%, (8.1 ± 0.07)% and (16.3 ± 0.13)% at 20 µmol/L of hemin treatment for 8,16, and 24 h respectively. Hemin induced apoptosis of K562/A02-IM cells in a dose-dependent manner. The expression of HO-1 was induced in K562/A02-IM cells in a dose-dependent manner, and the survival of K562/A02-IM cells was significantly increased as compared to that of control group. When HO-1 was inhibited by ZPP, the cells survival was sharply decreased compared to that of the control group (P < 0.05).
Conclusion:
HO-1 was expressed in the BMMNCs. It is a kind of molecules whose expression can be induced and can promote the growth of drug-resistant cells. Inhibition of HO-1 expression probably be used for the treatment of drug-resistant CML.
Insights
Heme oxygenase-1 (HO-1) promotes the growth of imatinib-resistant chronic myeloid leukemia (CML) cells. Inhibiting HO-1 expression offers a potential therapeutic strategy for drug-resistant CML.
Area of Science:
- Hematology
- Molecular Biology
- Cancer Research
Background:
- Imatinib resistance is a significant challenge in treating chronic myeloid leukemia (CML).
- Heme oxygenase-1 (HO-1) is an enzyme involved in cellular stress responses.
- The role of HO-1 in drug-resistant CML remains to be fully elucidated.
Purpose of the Study:
- To investigate the effect of HO-1 expression on cell growth and apoptosis in imatinib-resistant CML cells (K562/A02-IM).
- To explore the relationship between the HO-1 gene and CML progression and drug resistance.
Main Methods:
- Detected HO-1 expression in drug-resistant CML patients using RT-PCR.
- Induced HO-1 expression in K562/A02-IM cells with hemin and analyzed expression levels via RT-PCR and Western blot.
- Assessed cell apoptosis using Annexin V/PI staining and cell viability using MTT assay after HO-1 modulation.
Main Results:
- HO-1 was expressed in bone marrow mononuclear cells (BMMNCs) of CML patients.
- Hemin treatment dose-dependently increased HO-1 expression and induced apoptosis in K562/A02-IM cells.
- HO-1 induction promoted K562/A02-IM cell survival, while inhibition with zinc protoporphyrin (ZPP) significantly decreased cell survival.
Conclusions:
- HO-1 is expressed in BMMNCs and its induction promotes the growth of drug-resistant CML cells.
- HO-1 acts as a survival factor in imatinib-resistant CML.
- Inhibition of HO-1 presents a potential therapeutic approach for treating drug-resistant CML.
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic cells are...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

